Seminal
The magazine and atlas of EU-funded researchA new publication from the web and AI team at Scott Charnley

Atlas / Israel

European Research Council grant · Running

RE-ACT RNA Epithelial Approach for Crohn’s Treatment

Coordinator
Medical Research Infrastructure Development and Health Services Fund by the Sheba Medical Center, Israel
Runs
1 June 2025 to 30 November 2026
Status
Running
EU funding
€150k
Total cost
—
Partners
1 organisations in 1 countries
Type
European Research Council grant
Grant agreement
101212631

What the project is doing

In the project's own words, from its summary on CORDIS.

RE-ACT aims to translate groundbreaking ERC-funded research on lncRNA-based therapy for Crohn's Disease (CD) into a commercially viable treatment option. Our innovative approach targets the gut epithelial lining using lncRNA encapsulated in lipid nanoparticles (LNPs), addressing a critical gap in current CD treatments which primarily focus on immune suppression. By restoring epithelial function, we aim to achieve better mucosal healing and long-term patient outcomes.

Building on our discovery of widespread lncRNA dysregulation in CD patients, we will conduct comprehensive preclinical studies to validate the efficacy and safety of our lncRNA-LNP therapy. Our work will involve both ex-vivo studies using human cell models and in-vivo studies in mouse models of epithelial injury and gut inflammation, focusing on optimizing delivery, assessing therapeutic effects, and evaluating potential systemic impacts.

Concurrently, we will develop a robust IP strategy to protect our innovation, conduct thorough market assessments to understand the commercial landscape and engage in targeted business development activities to secure partnerships and funding for future clinical development. Our integrated approach combines scientific rigor with commercial acumen, maximizing the potential for successful translation from laboratory to clinic.

The project addresses a significant unmet medical need in CD treatment, potentially offering a more effective and targeted therapy with fewer systemic side effects. If successful, our lncRNA-based approach could not only improve outcomes for CD patients but also pave the way for similar therapies in other gastrointestinal disorders. By combining cutting-edge science with strategic commercial development, this project represents a significant step towards addressing the limitations of current CD treatments and improving the lives of millions affected by this challenging condition.

Topics

Who is involved

OrganisationCityCountryRole
Medical Research Infrastructure Development and Health Services Fund by the Sheba Medical CenterRamat GanIsraelCoordinator

Source: CORDIS, European Commission. Data of 5 Nov 2026, reused under the Commission's reuse policy. View on CORDIS · Grant DOI